Cargando…
Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new target...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/ https://www.ncbi.nlm.nih.gov/pubmed/36361639 http://dx.doi.org/10.3390/ijms232112849 |
_version_ | 1784829883025719296 |
---|---|
author | Bellinato, Francesco Chiricozzi, Andrea Piaserico, Stefano Targher, Giovanni Gisondi, Paolo |
author_facet | Bellinato, Francesco Chiricozzi, Andrea Piaserico, Stefano Targher, Giovanni Gisondi, Paolo |
author_sort | Bellinato, Francesco |
collection | PubMed |
description | Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient’s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient’s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient’s quality of life. |
format | Online Article Text |
id | pubmed-9658165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96581652022-11-15 Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? Bellinato, Francesco Chiricozzi, Andrea Piaserico, Stefano Targher, Giovanni Gisondi, Paolo Int J Mol Sci Review Chronic plaque psoriasis is an immune-mediated skin disease with a chronic relapsing course, affecting up to ~2–3% of the general adult population worldwide. The interleukin (IL)-23/Th17 axis plays a key role in the pathogenesis of this skin disease and may represent a critical target for new targeted pharmacotherapies. Cutaneous lesions tend to recur in the same body areas, likely because of the reactivation of tissue-resident memory T cells. The spillover of different pro-inflammatory cytokines into systemic circulation can promote the onset of different comorbidities, including psoriatic arthritis. New targeted pharmacotherapies may lead to almost complete skin clearance and significant improvements in the patient’s quality of life. Accumulating evidence supports the notion that early intervention with targeted pharmacotherapies could beneficially affect the clinical course of psoriatic disease at three different levels: (1) influencing the immune cells infiltrating the skin and gene expression, (2) the prevention of psoriasis-related comorbidities, especially psoriatic arthritis, and (3) the improvement of the patient’s quality of life and reduction of cumulative life course impairment. The main aim of this narrative review is to summarize the effects that new targeted pharmacotherapies for psoriasis may have on the immune scar, both at the molecular and cellular level, on psoriatic arthritis and on the patient’s quality of life. MDPI 2022-10-25 /pmc/articles/PMC9658165/ /pubmed/36361639 http://dx.doi.org/10.3390/ijms232112849 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bellinato, Francesco Chiricozzi, Andrea Piaserico, Stefano Targher, Giovanni Gisondi, Paolo Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title | Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title_full | Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title_fullStr | Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title_full_unstemmed | Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title_short | Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis? |
title_sort | could targeted pharmacotherapies exert a “disease modification effect” in patients with chronic plaque psoriasis? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658165/ https://www.ncbi.nlm.nih.gov/pubmed/36361639 http://dx.doi.org/10.3390/ijms232112849 |
work_keys_str_mv | AT bellinatofrancesco couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis AT chiricozziandrea couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis AT piasericostefano couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis AT targhergiovanni couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis AT gisondipaolo couldtargetedpharmacotherapiesexertadiseasemodificationeffectinpatientswithchronicplaquepsoriasis |